A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Director Regulatory Affairs - Global Labeling Strategy

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeUnited States$201.7k - $272.9kIn-person

About the Job

Requirements

  • A BS/BA degree is required; a science or related discipline is preferred, and a graduate degree is desirable.
  • At least 12 years of professional experience in the biopharmaceutical industry in Regulatory Affairs, Pharmacovigilance, and/or Medical Writing/Communications.
  • At least 7–8 years of experience in Regulatory Affairs, including at least 5 years of experience in labeling strategy.
  • Thorough knowledge of US, EU, and global regulations, standards, and guidance documents related to pharmaceutical product labeling.
  • Demonstrated ability to create and gain approval for labeling strategies that connect target claims to study design, endpoint selection, analysis, and the evidence package.
  • Strong strategic judgment and creativity to formulate new, credible, and differentiated approaches beyond describing precedents.
  • Ability to synthesize regulatory intelligence, literature research, competitor analysis, and data into actionable recommendations.
  • Curiosity and practical experience with AI-enabled research and productivity tools, with disciplined source verification, confidentiality protection, and accountable human oversight.
  • Track record of influencing cross-functional teams, constructively challenging assumptions, and communicating strategic choices to senior stakeholders.
  • Excellent drafting, facilitation, negotiation, and written and verbal communication skills.
  • Ability to organize and manage multiple complex programs while balancing strategic ambition with executional rigor.
  • Ability to work independently and represent the Global Labeling position.
  • Ability to remain current on emerging clinical and safety data, manufacturing changes, post-marketing commitments, and regulatory developments that may affect the CCDS or regional and local labeling.
  • Track record of developing and maintaining Target Label Profiles, Company Core Data Sheets, Standard Operating Procedures, and Work Instructions, and managing or coordinating core labeling activities.

Responsibilities

  • Lead Alnylam’s US Labeling function as part of the Global Labeling team in Regulatory Affairs, building scalable capabilities and processes to support the company’s growth as a commercial organization.
  • Provide strategic leadership in building and refining global labeling strategy processes and capabilities; guide development and maintenance of Company Core Data Sheets, country product information, and Target Label Profiles for investigational therapies or uses.
  • Apply scientific understanding across disease and therapy areas to interpret data and determine its strategic implications for labeling.
  • Ensure implementation of differentiated global labeling strategies and Target Label Profiles that articulate intended product value, priority claims, evidence requirements, risks, and negotiation pathways.
  • Translate labeling strategy into actionable evidence plans by partnering with Clinical Development, Biostatistics, Medical, Safety, Regulatory, and Market Access teams.
  • Influence study design and endpoint selection by identifying primary, secondary, exploratory, patient-relevant, and other evidence elements needed to support compelling and defensible labeling claims.
  • Develop labeling options by synthesizing regulatory precedents, competitor positioning, health authority decisions, scientific literature, clinical practice, and evolving policy.
  • Use approved AI tools and advanced research approaches to accelerate intelligence gathering, identify patterns and evidence gaps, stress-test strategic options, and improve labeling recommendations; apply expert review, source verification, confidentiality controls, and regulatory judgment to AI-supported outputs.
  • Lead development of scenario-based claim strategies, including ambitious, target, and fallback positions, with evidence thresholds, trade-offs, and negotiation plans for key regions.
  • Represent Global Labeling, including US Labeling, on Regulatory Affairs governance forums and relevant cross-functional product, development, and product safety teams.
  • Provide strategic guidance on emerging labeling regulations, health authority expectations, competitor labels, labeling trends, and their implications for the development portfolio and marketed products.
  • Lead regional labeling development aligned with the CCDS and tailored to health authority requirements, local evidence expectations, and the global negotiation strategy.
  • Lead and oversee preparation of labeling briefing materials and responses to health authority questions, and support negotiations with evidence-based arguments and fallback positions.
  • Coordinate labeling activities with internal and external alliance partners and align stakeholders on strategic objectives, decision points, and accountabilities.
  • Partner with Labeling Operations, Regulatory Technology and Operations, and Supply Chain to ensure submission-ready labeling components comply with regulatory requirements; assist with health authority submissions as needed.
  • Plan for, hire, onboard, and mentor the Regulatory Labeling Strategy team as the company grows.
  • Support growth of the Global Labeling function and help design and build its systems and processes.

Desired Qualifications

  • Prior experience managing a team.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs